Compare Cronos Group Inc (CRON) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs InMode Ltd — how do they compare? Cronos Group Inc trades at $3.09 (market cap $1.14B), while InMode Ltd trades at $15.17 (market cap $872.08M). The key difference: Cronos Group Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| CRON | INMD | |
|---|---|---|
Market Cap | $1.14B | $872.08M |
Sector | Health | Technology |
52-Week High | $3.27 | $16.62 |
52-Week Low | $2.30 | $12.76 |
Enterprise Value | $341.13M | $375.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
InMode (INMD) trades at $15.17, down slightly by 0.13% today, with neutral technical signals and mixed earnings performance. The company maintains strong profitability with 76.52% gross margins and 20.69% net income margins, though Q1 2026 earnings missed expectations. Recent news highlights acquisition interest from Steel Partners at $16.75 per share and ongoing shareholder activism, creating both opportunity and uncertainty around corporate governance and valuation.
The stock presents a value opportunity with low P/E (12.52) and EV/EBITDA (5.37) multiples, but faces risks from earnings volatility, shareholder disputes, and potential undervaluation concerns. Analyst consensus leans neutral with 45% buy ratings, while technical indicators suggest range-bound trading near key support at $15. Investment appeal hinges on resolution of acquisition talks and sustained execution amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
